JP2010530364A - ポリペプチド、抗体可変ドメインおよびアンタゴニスト - Google Patents

ポリペプチド、抗体可変ドメインおよびアンタゴニスト Download PDF

Info

Publication number
JP2010530364A
JP2010530364A JP2010510888A JP2010510888A JP2010530364A JP 2010530364 A JP2010530364 A JP 2010530364A JP 2010510888 A JP2010510888 A JP 2010510888A JP 2010510888 A JP2010510888 A JP 2010510888A JP 2010530364 A JP2010530364 A JP 2010530364A
Authority
JP
Japan
Prior art keywords
variable domain
sequence
vegf
dom15
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530364A5 (cg-RX-API-DMAC10.html
Inventor
スチュワード，マイケル
プペッカ，マウゴジャータ
エム トムリンソン，イアン
エネヴァー，キャロリン
エス ジェスパース，ローレント
ディナック バツワンガラ，ティル
Original Assignee
ドマンティス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en
Application filed by ドマンティス リミテッド filed Critical ドマンティス リミテッド
Publication of JP2010530364A publication Critical patent/JP2010530364A/ja
Publication of JP2010530364A5 publication Critical patent/JP2010530364A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
JP2010510888A 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト Pending JP2010530364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93363207P 2007-06-06 2007-06-06
GBGB0724331.4A GB0724331D0 (en) 2007-12-13 2007-12-13 Compositions for pulmonary delivery
PCT/GB2008/050407 WO2008149150A2 (en) 2007-06-06 2008-06-04 Polypeptides, antibody variable domains and antagonists

Publications (2)

Publication Number Publication Date
JP2010530364A true JP2010530364A (ja) 2010-09-09
JP2010530364A5 JP2010530364A5 (cg-RX-API-DMAC10.html) 2011-07-21

Family

ID=39791116

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510888A Pending JP2010530364A (ja) 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2010510886A Expired - Fee Related JP5325211B2 (ja) 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2010510887A Active JP5444215B2 (ja) 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010510886A Expired - Fee Related JP5325211B2 (ja) 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2010510887A Active JP5444215B2 (ja) 2007-06-06 2008-06-04 ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Country Status (31)

Country Link
US (5) US8398979B2 (cg-RX-API-DMAC10.html)
EP (5) EP2162468A2 (cg-RX-API-DMAC10.html)
JP (3) JP2010530364A (cg-RX-API-DMAC10.html)
KR (4) KR20100018040A (cg-RX-API-DMAC10.html)
CN (4) CN101802004A (cg-RX-API-DMAC10.html)
AR (3) AR066850A1 (cg-RX-API-DMAC10.html)
AU (4) AU2008259590A1 (cg-RX-API-DMAC10.html)
BR (3) BRPI0813899A2 (cg-RX-API-DMAC10.html)
CA (6) CA2688434A1 (cg-RX-API-DMAC10.html)
CL (3) CL2008001676A1 (cg-RX-API-DMAC10.html)
CO (2) CO6251322A2 (cg-RX-API-DMAC10.html)
CR (2) CR11194A (cg-RX-API-DMAC10.html)
CY (1) CY1116762T1 (cg-RX-API-DMAC10.html)
DK (1) DK2162467T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2009000268A (cg-RX-API-DMAC10.html)
EA (5) EA200901494A1 (cg-RX-API-DMAC10.html)
ES (1) ES2546943T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20151024T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025899T2 (cg-RX-API-DMAC10.html)
IL (2) IL201398A0 (cg-RX-API-DMAC10.html)
MA (2) MA31403B1 (cg-RX-API-DMAC10.html)
MX (4) MX2009013137A (cg-RX-API-DMAC10.html)
NZ (1) NZ581372A (cg-RX-API-DMAC10.html)
PE (3) PE20090322A1 (cg-RX-API-DMAC10.html)
PL (1) PL2162467T3 (cg-RX-API-DMAC10.html)
PT (1) PT2162467E (cg-RX-API-DMAC10.html)
SG (2) SG182141A1 (cg-RX-API-DMAC10.html)
SI (1) SI2162467T1 (cg-RX-API-DMAC10.html)
TW (6) TW200918088A (cg-RX-API-DMAC10.html)
WO (3) WO2008149148A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200908470B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
JP2014523746A (ja) * 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2744055A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
MX2011008799A (es) * 2009-02-19 2011-09-27 Glaxo Group Ltd Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
CN105061593B (zh) 2009-02-19 2018-08-03 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
AR075505A1 (es) * 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
BR112012008831A2 (pt) * 2009-10-14 2019-09-24 Aileron Therapeutics Inc macrociclos de peptideomiméticos aprimorados.
AR078763A1 (es) 2009-10-27 2011-11-30 Glaxo Group Ltd Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
SG185437A1 (en) 2010-05-20 2012-12-28 Glaxo Group Ltd Improved anti-serum albumin binding variants
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
CA2808683A1 (en) 2010-08-20 2012-02-23 Glaxosmithkline Intellectual Property Development Limited Improved anti-serum albumin binding variants
KR101871008B1 (ko) * 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SMT201900520T1 (it) * 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
JP2016504918A (ja) * 2013-01-31 2016-02-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ タンパク質を製造する方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
RU2625010C1 (ru) * 2016-11-10 2017-07-11 Илья Петрович Приколаб Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
EP3703689A1 (en) * 2017-11-01 2020-09-09 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3807312A4 (en) 2018-05-30 2022-07-20 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT
JP7428661B2 (ja) * 2018-05-30 2024-02-06 中外製薬株式会社 Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド
EP3623798B1 (de) * 2018-09-13 2021-11-03 Euroimmun Medizinische Labordiagnostika AG Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
CN112955240B (zh) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 抗体FcRn结合的修饰
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス，インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
CN111454366B (zh) * 2019-01-21 2023-06-16 中国科学院深圳先进技术研究院 一种融合蛋白及其应用
JP7315967B2 (ja) * 2019-01-31 2023-07-27 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7473398B2 (ja) * 2020-05-28 2024-04-23 シスメックス株式会社 キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN113528560A (zh) * 2021-04-02 2021-10-22 苏州博腾生物制药有限公司 靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) * 2022-03-04 2023-06-16 华南理工大学 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用
CN115112704B (zh) * 2022-06-21 2025-07-15 中特检验集团有限公司 一种光热发电有机热载体热稳定性检测方法
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
CN119909772B (zh) * 2025-04-01 2025-06-20 安徽一帆新材料科技有限公司 用于净水的再生阴树脂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003388A2 (en) * 2004-06-30 2006-01-12 Domantis Limited Compositions and methods for treating inflammatory disorders
US20070003549A1 (en) * 2004-08-24 2007-01-04 Olga Ignatovich Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2007049017A2 (en) * 2005-10-24 2007-05-03 Domantis Limited Agents that bind a target in pulmonary tissue for treating respiratory diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
ATE358177T1 (de) 1997-07-07 2007-04-15 Medical Res Council Ein in vitro sortierverfahren
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001057065A2 (en) 2000-02-03 2001-08-09 Domantis Limited Combinatorial protein domains
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7164009B2 (en) * 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003388A2 (en) * 2004-06-30 2006-01-12 Domantis Limited Compositions and methods for treating inflammatory disorders
US20070003549A1 (en) * 2004-08-24 2007-01-04 Olga Ignatovich Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2007049017A2 (en) * 2005-10-24 2007-05-03 Domantis Limited Agents that bind a target in pulmonary tissue for treating respiratory diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
JP2014523746A (ja) * 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン

Also Published As

Publication number Publication date
HUE025899T2 (en) 2016-05-30
EA018129B1 (ru) 2013-05-30
KR20100021642A (ko) 2010-02-25
PT2162467E (pt) 2015-10-29
CA2683823A1 (en) 2008-12-11
US20120134982A1 (en) 2012-05-31
AU2008259516A1 (en) 2008-12-11
KR20100018040A (ko) 2010-02-16
JP5444215B2 (ja) 2014-03-19
IL202204A0 (en) 2010-06-16
DK2162467T3 (en) 2015-08-24
CN104311663B (zh) 2018-11-02
CN101802004A (zh) 2010-08-11
BRPI0812268A2 (pt) 2019-09-10
ZA200908470B (en) 2011-02-23
PE20090763A1 (es) 2009-07-10
CN101778865A (zh) 2010-07-14
EA200901495A1 (ru) 2010-10-29
US20110256122A1 (en) 2011-10-20
WO2008149149A3 (en) 2009-04-02
AU2008259590A1 (en) 2008-12-11
TW200911832A (en) 2009-03-16
BRPI0812795B1 (pt) 2019-12-03
KR20100041746A (ko) 2010-04-22
US20100266616A1 (en) 2010-10-21
EP2164867A2 (en) 2010-03-24
EP2162467A2 (en) 2010-03-17
WO2008149148A2 (en) 2008-12-11
IL201398A0 (en) 2010-05-31
AU2008259514B2 (en) 2014-05-15
MA31403B1 (fr) 2010-05-03
CR11194A (es) 2010-06-28
BRPI0813899A2 (pt) 2019-09-24
SG182141A1 (en) 2012-07-30
KR20100040841A (ko) 2010-04-21
TW200911831A (en) 2009-03-16
US20090148437A1 (en) 2009-06-11
US20100247515A1 (en) 2010-09-30
ES2546943T3 (es) 2015-09-30
NZ581372A (en) 2012-02-24
EP2746290A3 (en) 2014-09-10
SI2162467T1 (sl) 2015-11-30
EP2746290B1 (en) 2019-08-14
WO2008149150A3 (en) 2009-06-25
EP2162467B1 (en) 2015-07-22
AR066850A1 (es) 2009-09-16
CO6251322A2 (es) 2011-02-21
CN104311663A (zh) 2015-01-28
AR066848A1 (es) 2009-09-16
CR11195A (es) 2010-05-24
WO2008149150A2 (en) 2008-12-11
DOP2009000268A (es) 2010-02-28
AU2008259514A1 (en) 2008-12-11
EP2746291B1 (en) 2019-08-14
EA200901491A1 (ru) 2010-08-30
SG182151A1 (en) 2012-07-30
JP2010530220A (ja) 2010-09-09
CY1116762T1 (el) 2017-03-15
MX2009013211A (es) 2010-04-09
CN101778865B (zh) 2016-11-09
PE20090322A1 (es) 2009-04-20
MX2009013137A (es) 2010-04-30
WO2008149149A2 (en) 2008-12-11
CA2688447C (en) 2016-11-08
BRPI0812795B8 (pt) 2020-01-28
EP2162468A2 (en) 2010-03-17
TW200918088A (en) 2009-05-01
PE20090323A1 (es) 2009-04-20
EA201100546A1 (ru) 2011-12-30
EA200901494A1 (ru) 2010-06-30
HRP20151024T1 (hr) 2015-11-06
MA31668B1 (fr) 2010-09-01
MX2009012967A (es) 2010-04-01
BRPI0812795A2 (pt) 2014-12-02
JP2010529841A (ja) 2010-09-02
EA018723B1 (ru) 2013-10-30
TW200907128A (en) 2009-02-16
KR101604274B1 (ko) 2016-03-17
CA2688433A1 (en) 2008-12-11
EP2746291A3 (en) 2014-09-03
TW200911834A (en) 2009-03-16
US8398979B2 (en) 2013-03-19
JP5325211B2 (ja) 2013-10-23
AR066847A1 (es) 2009-09-16
TW200902551A (en) 2009-01-16
CA2688434A1 (en) 2008-12-11
CL2008001673A1 (es) 2008-11-21
CO6251321A2 (es) 2011-02-21
CA2683791A1 (en) 2008-12-11
CA2688447A1 (en) 2008-12-11
EP2746290A2 (en) 2014-06-25
WO2008149148A3 (en) 2009-04-02
EA200901300A1 (ru) 2010-06-30
HK1138022A1 (en) 2010-08-13
CN101883788A (zh) 2010-11-10
MX2009013138A (es) 2010-04-30
CL2008001676A1 (es) 2008-11-21
EP2746291A2 (en) 2014-06-25
AU2008259515A1 (en) 2008-12-11
BRPI0812795C1 (pt) 2021-05-25
CL2008001674A1 (es) 2008-11-21
CA2688456A1 (en) 2008-12-11
PL2162467T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
JP5325211B2 (ja) ポリペプチド、抗体可変ドメインおよびアンタゴニスト
US8877186B2 (en) Polypeptides, antibody variable domains and antagonists
JP2010529840A (ja) ポリペプチド、抗体可変ドメインおよびアンタゴニスト
HK1138022B (en) Polypeptides, antibody variable domains & antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702